1 June 2023 - The price setting provisions in the Inflation Reduction Act acutely impact the research and development (R&D) of cancer medicines, a new analysis from the Partnership for Health Analytic Research demonstrates.

According to the analysis, a significant amount of the progress made in cancer treatment has been the result of the development of small molecule medicines (like pills and tablets) and continued research after a medicine has been approved (known as post-approval R&D) — both of which are discouraged under the law.

Read PhRMA press release